

**TIMOLOL MALEATE AND TIMOLOL – BRIMONIDINE COMBINATION IN TREATMENT OF OPEN-ANGLE GLAUCOMA PATIENTS: A COMPETITIVE STUDY**

**Kanchan Sharma & Pawanpreet Kaur** Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab

**ABSTRACT**

**Aim:** Timolol maleate and timolol – brimonidine combination in treatment of open-angle glaucoma patients.

**Methods:** This observational comparative was carried out in the Department of Pharmacology. The total number of cases comprises of 200, with 100 in each group. In some patients both their eyes were involved hence I.O.P was measured separately. The concentration of the monotherapy was 0.5% w/v Timolol Maleate. The concentration of the combination therapy was 0.2% w/v Brimonidine Tartrate and 0.5% w/v Timolol Maleate. Both drugs were instilled in the affected eye, twice daily (once in morning and once at night), for a period of four weeks.

**Results:** Around 41% was present with both DM (Type 1) and Hypertension in case of monotherapy of timolol. In the case of Timolol-Brimonidine combination, 54% of the patients presented with DM (type 1) and 52% of the patients with Hypertension. This slight increase may be due to the increase in the age of the patients undergoing combination therapy when compared to monotherapy. While 50% of the patients in both the groups had POAG in both their eyes, the remaining patients developed POAG in either the right eye or the left eye. The other eye was only suspected to have glaucoma and the IOP was less than 20mmHg. Hence the sample size to test the efficacy of the drug therapy is a total of 300 eyes, with 150 under each group. Monotherapy of Timolol is seen to lower the IOP at 26.77 in 3 days, whereas the Timolol-Brimonidine combination therapy lowers the IOP at twice the rate that is 44.77 in 3 days. After reaching a I.O.P of 12mmHg, which is the normal IOP, both the drugs are used for maintenance therapy.

**Conclusion:** Timolol monotherapy provides the same result as the Timolol-Brimonidine combination therapy and is also comparatively cheaper. Therefore, Timolol monotherapy is better suited for the treatment of POAG in a tertiary care hospital.

**Introduction**

The importance of controlling intraocular pressure (IOP) in glaucoma has been firmly established. It is also well known that many patients require 2 or more medications to reach their target IOP. Accordingly, the mainstay of therapy for primary open-angle glaucoma (POAG) and ocular hypertension (OHT) consists of IOP-lowering agents such as prostaglandin analogues/prostamide, b-blockers, and  $\alpha_2$ -adrenergic receptor agonists, which are often used in combination due to their complementary mechanisms of action.<sup>1-3</sup> Target IOP levels are not always achieved with the use of one agent, however, and many patients require combination therapy. Several new and effective IOP lowering drugs have additive effects when used in combination with the b-adrenergic receptor antagonist timolol.<sup>4-6</sup> Latanoprost, the only prostaglandin analogue indicated for first line use as an ocular hypotensive in Europe and the United States, lowers IOP levels by increasing uveoscleral outflow with little or no effect on aqueous humour production, while b blockers are believed to reduce aqueous humour formation.<sup>7-9</sup> The concomitant administration of latanoprost and timolol produces an additive IOP reducing effect.<sup>10,11</sup> Because complex, multidrug regimens can reduce patient compliance, a fixed formulation of latanoprost 0.005% and timolol 0.5% has been made available. Once daily administration of this combination is well tolerated and reduces IOP more effectively than either individual component alone in patients with open angle glaucoma and ocular hypertension.<sup>12-15</sup> Brimonidine, a selective  $\alpha_2$  agonist ocular hypotensive agent, acts by reducing aqueous humour production and increasing uveoscleral outflow.<sup>16</sup> Compared with timolol in patients with open angle glaucoma or ocular hypertension, brimonidine dosed twice daily produces similar or significantly lower IOP levels when measured 2 hours after a morning dose.

Twelve hours after the evening dose (trough), mean decreases in IOP are consistently and significantly greater in timolol treated patients, supporting the brimonidine labelling recommendation of three times daily dosing.<sup>16</sup> This study compares the effect on IOP of the fixed combination (FC) of latanoprost 0.005% and timolol 0.5% with that of the unfixed combination (UFC) of brimonidine 0.2% and timolol 0.5% in patients with open angle glaucoma or ocular hypertension who previously were uncontrolled on monotherapy or dual therapy. Although the recommended brimonidine dosing regimen is three times daily, twice daily dosing appears to be standard practice

### **Material and methods**

This observational comparative was carried out in the Department of Pharmacology, after taking the approval of the protocol review committee and institutional ethics committee. Patients of Primary Open Angle Glaucoma (POAG) Of age group  $\geq 30$  years were included in this study. Person has other complications relating to IOP, Person is taking medications other than those described above OR Person is taking additional medication to lower IOP, When I.O.P is higher than normal but person doesn't show signs of glaucoma and Patients with a history of bronchial asthma, COPD and cardiac diseases were excluded from this study.

The total number of cases comprises of 200, with 100 in each group. In some patients both their eyes were involved hence I.O.P was measured separately.

The concentration of the monotherapy was 0.5% w/v Timolol Maleate. The concentration of the combination therapy was 0.2% w/v Brimonidine Tartrate and 0.5% w/v Timolol Maleate. Both drugs were instilled in the affected eye, twice daily (once in morning and once at night), for a period of four weeks.

The measurement of IOP was done every three days in the morning using Goldmann Applanation Tonometry, which is the gold standard procedure for the measurement of IOP.

### **Procedure of measurement of IOP by Goldmann Applanation Tonometry**

The IOP was measured after the administration of the local anaesthetic drops in order to block the transmission of pain signals, and the fluorescein strips were used to stain the eyes. The beam of the slit on tonometer was adjusted towards the right side of the patient during the IOP measurement of the right eye, while it can be adjusted to the left-hand side of the patient during the IOP measurement of the left eye. Blue and green filters are moved to produce the coloured beam. The beam produced was bright making the fluorescein rings more visible. After fixing the gaze, the patient was asked to look straight with eyes opened widely. By using the thumb, the patient's eyelid must be held gently without applying much pressure on the eye. The blue light from the slit lamp was directed towards the prism ensuring that the head is perpendicular to the eye. The tonometer was slowly moved forward until the prism rests at the centre of the cornea. Using the other hand, the calibrated dial on the tonometer was turned clockwise until the two fluorescein circles in the prism were observed to meet forming a horizontal "S" shape. The readings on the dial were recorded after withdrawing the prism from the corneal surface. The same procedure was repeated for the other eye after wiping the prism with a disinfectant swab.

Once the IOP was lowered to 12mmHg, the drugs were continued to be instilled twice daily for the remaining duration of the study, as a part of the maintenance therapy.

### **Statistical Analysis**

The data collected will be analyzed using Descriptive and Inferential statistics, and the Statistical Software used for Data Analysis is SPSS V23.0 .

### **Results**

Study was conducted on a total of 200 patients of POAG, with 100 patients undergoing monotherapy of Timolol Maleate and the remaining 100 undergoing the combination therapy of Timolol-Brimonidine combination. There was not much of a significant difference in the gender of the patients, both males and females were affected equally in case of the combination therapy, and the preponderance of female patients (54%) was seen in case of monotherapy of timolol. There was no direct correlation to the presence of comorbidities in the patients. Around 41% was present with both DM (Type 1) and Hypertension in case of monotherapy of timolol. In the case of Timolol-Brimonidine combination, 54% of the patients presented with DM (type 1) and 52% of the patients with Hypertension. This slight increase may be due to the increase in the age of the patients undergoing combination therapy when compared to monotherapy. While 50% of the patients in both the groups had POAG in both their eyes, the remaining patients developed POAG in either the right eye or the left eye. The other eye was only suspected to have glaucoma and the IOP was less than 20mmHg. Hence the sample size to test the efficacy of the drug therapy is a total of 300 eyes, with 150 under each group. Monotherapy of Timolol is seen to lower the IOP at 26.77 in 3 days, whereas the Timolol-Brimonidine combination therapy lowers the IOP at twice the rate that is 44.77 in 3 days. After reaching a I.O.P of 12mmHg, which is the normal IOP, both the drugs are used for maintenance therapy.

Adverse effects were reported with the usage of both the drug therapies. Dryness of eyes was seen in 4% of the patients in both cases. With the Timolol-Brimonidine combination therapy, an additional redness of eyes was seen in 4% of patients, which was not reported in case of monotherapy of Timolol.

**Table 1:** Comparison between Timolol Maleate and Timolol- Brimonidine combination with respect to the demographic details

Demographic Details	Timolol Maleate		Timolol-Brimonidine Combination	
	No. (n=100)	Percentage.	No. (n=100)	Percentage
<b>Age</b>				
Less than 30 years	6	6	0	0
35 to 50 years	16	16	26	26
50 to 65 years	62	62	38	38
65 years and above	16	16	36	36
<b>Gender</b>			<b>50</b>	<b>50</b>
Male	46	46		
Female	54	54	50	50
<b>Comorbidities</b>	<b>41</b>	<b>41</b>		
Diabetes Mellitus (Type 1)			54	54
Hypertension	41	41	52	52

**Table 2:** Comparison between Timolol Maleate and Timolol- Brimonidine combination with respect to the efficacy of lowering the I.O.P in POAG

No. of Days	Timolol Maleate I.O.P	Timolol- Brimonidine I.O.P
	Measured(150 eyes) (mmHg)	Measured (mmHg)
0	58.60	58.66
3	52.59	40.55
6	40.75	40.75
9	40.75	40.75
12	40.75	40.75
15	40.75	40.75
21	40.75	40.75

28	40.75	40.75
----	-------	-------

**Table 3:** Comparison between Timolol Maleate and Timolol- Brimonidine combination with respect to the adverse effects (if seen)

Adverse Effects	Timolol Maleate(150 eyes)	Timolol-Brimonidine(150 eyes)
		Combination
Dryness of eyes	8 (4%)	8 (4%)
Redness of eyes	0 (0%)	8 (4%)

### Discussion

Glaucoma is a group of diseases characterized by a progressive form of optic nerve damage. This is generally, but not necessarily, associated with raised (>21mm Hg) intra ocular pressure (IOP) but the etiology is unknown and there are many risk factors. The chief therapeutic measure is to lower the IOP, either by reducing the secretion of aqueous humor or by promoting its drainage.<sup>5</sup>

Timolol is the prototype of ocular beta blockers. It is non- selective and has no local anaesthetic or sympathomimetic activity. The ocular hypotensive action (20-35% fall in IOP) becomes evident within 1 hour and lasts for 12 hours.

Brimonidine, on the other hand, is a selective alpha adrenoceptor agonist used as second line add on drug for glaucoma to supplement ocular prostaglandin analogues/beta-blockers. Brimonidine is more alpha 2 selective and more lipophilic. It lowers IOP by 20-27% by reducing aqueous production and by increasing the uveoscleral flow. Peak effect occurs after 2 hours of instillation. Allergic conjunctivitis and other ocular side effects are present.<sup>17-21</sup>

Timolol monotherapy and Timolol-Brimonidine combination therapy are equally effective in lowering and maintaining the IOP of a patient of POAG. Though Timolol-Brimonidine combination therapy was initially faster in the reduction of IOP, there is no difference in the efficacy of both the therapies, in maintaining the IOP at an optimum of 12mmHg. Hence, the result is the same as that of the monotherapy, with both drugs being equally effective. This result is similar to the various studies conducted across India, where Timolol-Brimonidine combination therapy was faster in lowering the IOP when compared to Timolol monotherapy. However, both the drugs were equally effective in lowering to the optimum IOP and in maintaining it. Both the Timolol Monotherapy and Timolol-Brimonidine combination therapy bring the IOP to a normal level. The IOP was maintained at a constant of 12mmHg as a part of the maintenance therapy for the remaining duration of the study. With respect to the cost, the Timolol monotherapy is priced lower, when compared to Timolol-Brimonidine combination therapy, which is significantly higher.

The study was conducted on a total of 200 patients of POAG, with 100 patients undergoing monotherapy of Timolol Maleate and the remaining 50 undergoing the combination therapy of Timolol-Brimonidine combination.

The comparison of the monotherapy of timolol versus timolol-brimonidine combination therapy with respect to the Demographic details is seen in Table 1. With the monotherapy of timolol, 62% of the patients belonged to the age group of 50-65 years and only 16% of the patients were above 65 years. With Timolol- Brimonidine combination therapy, the patients were significantly older, with 38% of the patients belonging to the age group of 50-65 years and 36% of the patients of the above 65 years. There was not much of a significant difference in the gender of the patients, both males and females were affected equally in case of the combination therapy, and the preponderance of female patients (54%) was seen in case of monotherapy of timolol.

There was no direct correlation to the presence of comorbidities in the patients. Around 41% was present with both DM (Type 1) and Hypertension in case of monotherapy of timolol. In the case of Timolol-Brimonidine combination, 54% of the patients presented with DM (type 1) and 52% of the

patients with Hypertension. This slight increase may be due to the increase in the age of the patients undergoing combination therapy when compared to monotherapy.

While 50% of the patients in both the groups had POAG in both their eyes, the remaining patients developed POAG in either the right eye or the left eye. The other eye was only suspected to have glaucoma and the IOP was less than 20mmHg. Hence the sample size to test the efficacy of the drug therapy is a total of 300 eyes, with 150 under each group. similar study was conducted by some other authors.<sup>22</sup>

Monotherapy of Timolol is seen to lower the IOP at 26.77 in 3 days, whereas the Timolol-Brimonidine combination therapy lowers the IOP at twice the rate that is 44.77 in 3 days. After reaching a I.O.P of 12mmHg, which is the normal IOP, both the drugs are used for maintenance therapy. compares the efficacies of both the therapies, up to day 12.

Adverse effects were reported with the usage of both the drug therapies. Dryness of eyes was seen in 4% of the patients in both cases. With the Timolol-Brimonidine combination therapy, an additional redness of eyes was seen in 4% of patients, which was not reported in case of monotherapy of Timolol.

### **Conclusion**

Timolol monotherapy provides the same result as the Timolol-Brimonidine combination therapy and is also comparatively cheaper. Therefore, Timolol monotherapy is better suited for the treatment of POAG in a tertiary care hospital.

### **Reference**

1. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2002;120:1268e1279.
2. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2003;121:48e56.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol*. 2002;120:701e713. Discussion 829e830.
4. Hartenbaum D. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open- angle glaucoma and ocular hypertension. *Clin Ther* 1996;18:460–5.
5. Diestelhorst M, Almega°rd B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. *Graefe’s Arch Clin Exp Ophthalmol* 1998;236:577–81.
6. Garc’ia-Sa’nchez J, and the Spanish Latanoprost Study Group. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension—a three-month randomised study. *Eur J Ophthalmol* 2000;10:198–204.
7. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F<sub>2a</sub> analog, on aqueous humor dynamics in human eyes. *Ophthalmology* 1993;100:1297–304.
8. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F<sub>2a</sub> analogue, after topical application in normal and ocular hypertensive human eyes. *Arch Ophthalmol* 1993;111:1351–8.
9. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. *Arch Ophthalmol* 1978;96:2045–8.
10. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F<sub>2a</sub> analogue, and timolol in patients with elevated intraocular pressure. *Br J Ophthalmol* 1994;78:899–902.

11. Bucci MG, and the Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. *J Glaucoma* 1999;8:24–30.
12. Weinreb RN. Compliance with medical treatment of glaucoma. *J Glaucoma* 1992;1:134–6.
13. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. *Ophthalmic Surg* 1995;26:233–6.
14. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. *Arch Ophthalmol*, 2002;120:915–22.
15. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. *Graefe's Arch Clin Exp Ophthalmol* 2002;240:893–9.
16. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. *Arch Ophthalmol* 1995;113:1514–917.
17. Quigley HA. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol*. 2006;90(3):262–7. doi:10.1136/bjo.2005.081224.
18. Ocansey S, Abu EK, Abraham CH, Owusu-Ansah A, Acheampong C, Mensah F. Socio-demographic factors modify awareness, knowledge, and perceived risk of glaucoma in rural and urban residents in Ghana: a population-based survey. *Ther Adv Ophthalmol*. 2021;13. doi:10.1177/2515841421998099.
19. Chandrashekhara S, Rengappa R, Gunaselvi R, Maheshwari D, Kader MA, Chakrabarty S. Agreement of findings of glaucoma screening between trained vision center technicians and glaucoma specialists at a tertiary hospital in South India. *Indian J Ophthalmol*. 2021;69(4):871–5. doi:10.4103/ijo.ijo\_1390\_20.
20. Hu D, Jiang J, Lin Z, Zhang C, Moonasar N, Qian S. Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis. *Int J Med Sci*. 2021;18(7):1554–65. doi:10.7150/ijms.52846.
21. Tripathi KD. *Essentials of Medical Pharmacology*. 8th ed. Replika Press; 2019
22. Parameswaran R, Satyanarayana V, Nithisha T M. Comparative study between timolol maleate and timolol - brimonidine combination in treatment of open-angle glaucoma of moderate intraocular pressure in a tertiary care hospital. *Indian J Pharm Pharmacol* 2021;8(2):151-155.